|
|
 |
|
 |
|
|
|
|
Title:
|
A Phase II Trial of Response-Adapted Therapy of Stage III-IV Hodgkin Lymphoma using Interim FDG-PET Imaging - IRB# 09-089A
|
|
Treatments:
|
Bleomycin, Cyclophosphamide, Dacarbazine, Doxorubicin, Etoposide, Prednisone, Procarbazine, Vinblastine, Vincristine
|
|
Disease Site:
|
Lymphoma
|
|
Disease SubSite:
|
Hodgkins
|
|
Drug Provided:
|
-- none --
|
|
Comments:
|
PET after 2nd cycle provided.
|
|
Eligibility:
|
Histologically confirmed classical Hodgkin lymphoma (i.e., nodular sclerosis, mixed cellularity, lymphocyte-rich, or lymphocyte-depleted). Previously untreated stage III or IV disease. No nodular lymphocyte predominant disease. Bidimensionally measurable disease. Adequate biopsy samples from original diagnostic specimen must be available for pathologic review. Tissue obtained from core biopsies allowed
No tissue obtained from needle aspirations or cytologies. Must have known HIV status. No multi-drug resistant HIV infection, CD4 counts < 350/mcL, or other concurrent AIDS-defining conditions in HIV-positive patients. HIV-positive patients with CD4 counts => 350/mcL allowed. Must have undergone unilateral or bilateral bone marrow biopsy within the past 42 days. Prior/ Concurrent Therapy: See Disease Characteristics No prior chemotherapy, radiotherapy, or antibody therapy for lymphoma. No prior solid organ transplantation.
|
|
Participating Sites:
|
Adventist Medical Center, Northwest Cancer Specialists, Providence Milwaukie Hospital, Providence Portland Medical Center, Providence St. Vincent Medical Center, Southwest Washington Medical Center
|
|
|
|
|
 |
|
 |
|
|
|